Literature DB >> 7552293

Physiological levels of beta-amyloid increase tyrosine phosphorylation and cytosolic calcium.

Y Q Luo1, N Hirashima, Y H Li, D L Alkon, T Sunderland, R Etcheberrigaray, B Wolozin.   

Abstract

The a beta peptide is a neurotoxic peptide that accumulates in the brains of Alzheimer patients, but is also present in body fluids at subnanomolar levels. The potential effects of these low levels of a beta are unclear. We now show that one such action is to increase tyrosine phosphorylation in PC12 cells and olfactory neuroblasts. Application of a beta 25-35 or a beta 1-40 induces a dose-dependent increase in the tyrosine phosphorylation in both whole cells and in vitro. The increase in tyrosine phosphorylation is both rapid and sensitive, being stimulated by picomolar doses of a beta and occurring within 1 min of application. Calcium imaging experiments provide further support for the role of tyrosine phosphorylation in the action of a beta. While a beta does not alter calcium metabolism under basal conditions, the addition of a beta induces a rapid increase in cytoplasmic calcium in olfactory neuroblasts that have been treated with the tyrosine phosphatase inhibitor, sodium orthovanadate or in PC12 cells treated with nerve growth factor. These responses could be blocked by the tyrosine kinase inhibitor, herbimycin. These calcium responses displayed an obligate requirement for the presence of matrix proteins. The identification of a rapid, sensitive assay for the action of a beta may facilitate investigations of its mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552293     DOI: 10.1016/0006-8993(95)00282-u

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease.

Authors:  W G Wood; F Schroeder; N A Avdulov; S V Chochina; U Igbavboa
Journal:  Lipids       Date:  1999-03       Impact factor: 1.880

2.  Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases.

Authors:  Ritchie Williamson; Timothy Scales; Bruce R Clark; Graham Gibb; C Hugh Reynolds; Stuart Kellie; Ian N Bird; Ian M Varndell; Paul W Sheppard; Ian Everall; Brian H Anderton
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

3.  Probucol suppresses enterocytic accumulation of amyloid-β induced by saturated fat and cholesterol feeding.

Authors:  Menuka M Pallebage-Gamarallage; Susan Galloway; Ryusuke Takechi; Satvinder Dhaliwal; John C L Mamo
Journal:  Lipids       Date:  2011-07-31       Impact factor: 1.880

Review 4.  Targeting Fyn Kinase in Alzheimer's Disease.

Authors:  Haakon B Nygaard
Journal:  Biol Psychiatry       Date:  2017-06-13       Impact factor: 13.382

5.  Amyloid beta peptide impaired carbachol but not glutamate-mediated phosphoinositide pathways in cultured rat cortical neurons.

Authors:  H M Huang; H C Ou; S J Hsieh
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

6.  Effect of beta-amyloid block of the fast-inactivating K+ channel on intracellular Ca2+ and excitability in a modeled neuron.

Authors:  T A Good; R M Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

7.  Fyn depletion ameliorates tauP301L-induced neuropathology.

Authors:  Guanghao Liu; Kimberly L Fiock; Yona Levites; Todd E Golde; Marco M Hefti; Gloria Lee
Journal:  Acta Neuropathol Commun       Date:  2020-07-14       Impact factor: 7.801

Review 8.  Fyn kinase inhibition as a novel therapy for Alzheimer's disease.

Authors:  Haakon B Nygaard; Christopher H van Dyck; Stephen M Strittmatter
Journal:  Alzheimers Res Ther       Date:  2014-02-05       Impact factor: 6.982

9.  Monoclonal antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the Alzheimer's disease diagnosis.

Authors:  Kazuma Murakami; Maki Tokuda; Takashi Suzuki; Yumi Irie; Mizuho Hanaki; Naotaka Izuo; Yoko Monobe; Ken-Ichi Akagi; Ryotaro Ishii; Harutsugu Tatebe; Takahiko Tokuda; Masahiro Maeda; Toshiaki Kume; Takahiko Shimizu; Kazuhiro Irie
Journal:  Sci Rep       Date:  2016-07-04       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.